entertainment -WSS

entertainment

author：comprehensive 2025-10-02 06:02:23 - browse：6919

A caretaker speaks with an elderly Alzheimer's patient at a nursing home. — ALAIN JOCARD/AFP via Getty Images

For more than 30 years, Alzheimer’s researchers have thought of APOE4 as a major genetic risk factor for most cases of the devastating neurologic disease. But a new study published on Monday argues that this gene variant plays an even more important role than scientists had realized and causes a distinct form of Alzheimer’s.

Researchers analyzed data from more than 13,000 people, including nearly 800 APOE4 homozygotes, people who carry two copies of the gene variant. They found that nearly all of the homozygotes showed biological signs of Alzheimer’s in the brain, and they typically developed dementia and other symptoms, and died sooner, than people with Alzheimer’s who lack APOE4.

The research team also found that APOE4 homozygotes showed a predictable pattern of biomarker changes linked to Alzheimer’s, including a buildup of beta-amyloid and tau, a protein linked to neuron damage and death.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Why are elite athletes different? Take a look at their microbes

leisure time

WSS

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Gene therapy has helped boys walk. Can scientists keep it that way?

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

New guidelines on severe brain injury complicate already difficult decisions

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

leisure time

Cancer drug shortages should be causing more outrage

CDC concerned about possible undetected monkeypox spread in U.K.

Affirmative action in medical school literally saved lives

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Cancer drug shortages should be causing more outrage

Ask STAT: What do you want to know about ChatGPT in medicine?

What does generative AI mean for health care? We asked experts

Precocious puberty in girls comes with mental health risks

entertainment

The battle over the Brookhaven Landfill on Long Island

Amylyx ALS drug failure raises questions and concerns

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

First medicine developed to treat MASH expected to be approved soon

The problem with charging patients to message their doctors

The story of mRNA: From a loose idea to a tool that may help curb Covid

Wikipedia

leisure time

knowledge

leisure time